Literature DB >> 9456195

Legal issues in human clinical investigation: a primer for physicians.

A M Green1, N D Steinmetz.   

Abstract

Human clinical investigation plays a central role in contemporary nuclear cardiology. It is a complex expensive endeavor triggering multiple responsibilities not otherwise encountered by physicians in clinical practice. Clinical investigators, drug and device manufacturers, hospitals and universities, governmental agencies, research subjects, patient advocacy groups, and investors all have a legitimate interest in the conduct and the outcome of clinical research. Past abuses of research subjects in many countries including those unknowingly exposed to radioactive isotopes have raised ethical concerns that are now addressed by overlapping laws, regulations, guidelines, and institutional policies that have evolved to guide the research enterprise. The policies underlying this legal and regulatory structure include protection of research subjects, protection of the integrity of research design and research data, and protection of the public and private purse. Knowledge of these laws and regulations is essential for physicians participating in clinical investigations to protect their professional and personal interests. This article reviews legal issues relevant to physicians conducting human clinical trials in the United States.

Entities:  

Keywords:  Biomedical and Behavioral Research; Legal Approach

Mesh:

Year:  1997        PMID: 9456195     DOI: 10.1016/s1071-3581(97)90013-1

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  2 in total

1.  Declaration of Helsinki. Recommendations guiding medical doctors in biomedical research involving human subjects.

Authors: 
Journal:  Ugeskr Laeger       Date:  1976-02-09

2.  The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research.

Authors: 
Journal:  J Am Coll Dent       Date:  2014
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.